News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
294,503 Results
Type
Article (14351)
Company Profile (111)
Press Release (280041)
Section
Business (97409)
Career Advice (468)
Deals (17437)
Drug Delivery (63)
Drug Development (39910)
Employer Resources (49)
FDA (7050)
Job Trends (6616)
News (166245)
Policy (15466)
Tag
Academia (499)
Alliances (26520)
Alzheimer's disease (405)
Approvals (7039)
Artificial intelligence (59)
Bankruptcy (145)
Best Places to Work (4671)
Biosimilars (40)
Biotechnology (46)
Breast cancer (47)
Cancer (335)
Career advice (412)
Cell therapy (47)
Clinical research (33027)
Collaboration (143)
Compensation (55)
COVID-19 (846)
C-suite (50)
Data (334)
Diabetes (53)
Diagnostics (1695)
Drug pricing (56)
Earnings (35053)
Employer resources (43)
Events (40586)
Executive appointments (148)
FDA (7240)
Funding (104)
Gene therapy (61)
GLP-1 (296)
Government (1389)
Healthcare (4159)
Infectious disease (866)
Inflammatory bowel disease (50)
Interviews (58)
IPO (6674)
Job creations (2129)
Job search strategy (379)
Layoffs (169)
Legal (3761)
Lung cancer (52)
Manufacturing (92)
Medical device (2214)
Medtech (2217)
Mergers & acquisitions (10792)
Metabolic disorders (166)
Neuroscience (502)
NextGen Class of 2024 (1694)
Non-profit (628)
Northern California (429)
Obesity (100)
Opinion (109)
Patents (53)
People (30293)
Pharmaceutical (64)
Phase I (8770)
Phase II (14063)
Phase III (12330)
Pipeline (153)
Podcasts (39)
Policy (43)
Postmarket research (1445)
Preclinical (3534)
Radiopharmaceuticals (127)
Rare diseases (86)
Real estate (2900)
Regulatory (10831)
Research institute (602)
Resumes & cover letters (55)
Southern California (430)
Startups (1843)
United States (4271)
Vaccines (121)
Weight loss (76)
Date
Today (71)
Last 7 days (374)
Last 30 days (1202)
Last 365 days (14332)
2024 (12522)
2023 (16140)
2022 (22859)
2021 (23439)
2020 (22004)
2019 (16755)
2018 (13087)
2017 (15485)
2016 (14674)
2015 (17286)
2014 (13945)
2013 (11958)
2012 (12866)
2011 (13356)
2010 (12136)
Location
Africa (337)
Arizona (40)
Asia (30455)
Australia (3938)
California (987)
Canada (624)
China (132)
Connecticut (40)
Europe (44802)
Florida (133)
Illinois (108)
Indiana (81)
Japan (42)
Kansas (55)
Maryland (190)
Massachusetts (875)
Minnesota (68)
New Jersey (421)
New York (294)
North Carolina (290)
Northern California (429)
Pennsylvania (280)
South America (550)
Southern California (430)
Texas (125)
Washington State (68)
294,503 Results for "aslan pharmaceuticals pte ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
ASLAN Pharmaceuticals announced that it has signed a new research collaboration agreement with its partner, Zenyaku Kogyo Co., Ltd., to establish a framework for a succession of research projects to explore the differentiation of eblasakimab’s mechanism of action versus biologic therapies for atopic dermatitis, dupilumab and lebrikizumab.
May 2, 2024
·
7 min read
Biotech Bay
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
ASLAN Pharmaceuticals Ltd. announced today announced that it has entered into a definitive agreement for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares, each ADS representing twenty-five ordinary shares, at an offering price of $1.00 per ADS in a registered direct offering.
March 12, 2024
·
6 min read
Biotech Bay
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN) today announced it has received a favorable patentability opinion from the European Patent Office (EPO) acting as the International Examiner on a polymorph patent application for farudodstat which, if granted in the national stages, will extend effective patent protection for farudodstat until at least 2043.
February 29, 2024
·
5 min read
Business
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
ASLAN Pharmaceuticals announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.
May 9, 2024
·
14 min read
Biotech Bay
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN Pharmaceuticals Ltd. announced that it has begun to enroll patients in the US under an updated protocol in the ongoing TREK-DX trial, studying eblasakimab in dupilumab-experienced patients with moderate-to-severe atopic dermatitis.
March 11, 2024
·
10 min read
Business
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
ASLAN Pharmaceuticals Ltd. announced new positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of chronic obstructive pulmonary disease that provides further support for the potential of eblasakimab as a biologic therapy for COPD.
March 6, 2024
·
9 min read
Biotech Bay
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences - January 2, 2024
ASLAN Pharmaceuticals today announced its participation in upcoming conferences for January 2024.
January 2, 2024
·
1 min read
Business
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent corporate activities.
April 12, 2024
·
16 min read
Biotech Bay
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.
December 12, 2023
·
11 min read
Biotech Bay
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
ASLAN Pharmaceuticals announced the late-breaking poster presentation of translational data from head-to-head studies of eblasakimab and dupilumab in human healthy and COPD-derived lung tissue models at the American Thoracic Society International Conference 2024 in San Diego, California.
May 21, 2024
·
8 min read
1 of 29,451
Next